Dr. Tendler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
920 Route 202
Raritan, NJ 08869Phone+1 908-927-4772
Education & Training
Icahn School of Medicine at Mount Sinai/Kravis Children'sFellowship, Pediatric Hematology/Oncology, 1991 - 1992- Icahn School of Medicine at Mount Sinai/Kravis Children'sResidency, Pediatrics, 1985 - 1988
- Icahn School of Medicine at Mount SinaiClass of 1984
Certifications & Licensure
NJ State Medical License 1991 - 2025
NY State Medical License 1985 - 2025
MD State Medical License 1988 - 1991
Publications & Presentations
PubMed
- 69 citationsLenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialAndrzej Jakubowiak, Kent A. Griffith, Donna E. Reece, Craig C. Hofmeister, S. Lonial
Blood. 2011-07-21 - 97 citationsCytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.Craig L. Tendler, Steven J. Greenberg, Jack D. Burton, David Danielpour, Seong-Jin Kim
Journal of Cellular Biochemistry. 1991-08-01 - 35 citationsPredictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial...Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani
British Journal of Haematology. 2019-01-01
Journal Articles
- Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...David C Fajgenbaum, Craig Tendler, British Journal of Haematology
Press Mentions
Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO®-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not PlannedSeptember 30th, 2024- Update on IMBRUVICA® (Ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma IndicationsApril 6th, 2023
- (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host DiseaseAugust 24th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
